The remarkable association between certain EGFR mutations, especially exon 19 deletions or L858R mutation in exon 21 and clinical benefit in patients with NSCLC treated with EGFR tyrosine kinase inhibitors (TKIs), such as Gefitinib and Erlotinib, is well established [1-9,13-16,23]. Here, EGFR is linked to non-small cell lung carcinoma.